RxDoctor Payments Data

Mark Mosson, MD

Internal Medicine · San Diego, CANPI 1174765549

Payments from drug & device makers

$15,047in general payments, 2019–2025

Across 732 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Amgen$910
  • Lilly USA, LLC$866
  • Gilead$805
  • Novartis$790
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,985100%
  • Education$620%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,047 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$268,885
Medicare patients
525
Services billed
12,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$108,676
EliquisApixaban74$72,285
XareltoRivaroxaban54$63,480
MounjaroTirzepatide36$38,605
JardianceEmpagliflozin23$30,232
TrulicityDulaglutide16$28,518
JanuviaSitagliptin Phosphate29$24,688
Breo ElliptaFluticasone/Vilanterol35$19,425
FarxigaDapagliflozin Propanediol20$15,802
Repatha SureclickEvolocumab13$10,839
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,458
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,220
Dexlansoprazole DrDexlansoprazole13$6,045
Atorvastatin Calcium529$5,538
Celecoxib50$5,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$787$108,67683 claims
PfizerEliquis, Premarin, Paxlovid$677$77,669120 claims
Lilly USA, LLCMounjaro, Trulicity$866$67,12452 claims
Johnson & JohnsonXarelto$690$63,48054 claims
Boehringer IngelheimJardiance, Stiolto Respimat$373$38,45134 claims
MerckJanuvia$359$24,68829 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,109$24,26031 claims
GSKBreo Ellipta$717$19,42535 claims
AbbVieLumigan, Synthroid$2,523$5,13644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →